{"id":1052969,"date":"2010-10-11T10:14:50","date_gmt":"2010-10-11T10:14:50","guid":{"rendered":"http:\/\/www.immortalitymedicine.tv\/whats-new-in-hematology-from-uptodate\/"},"modified":"2024-08-17T18:47:12","modified_gmt":"2024-08-17T22:47:12","slug":"whats-new-in-hematology-from-uptodate","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/neurology\/whats-new-in-hematology-from-uptodate.php","title":{"rendered":"What’s new in hematology from UpToDate"},"content":{"rendered":"

\"\"<\/a>35% of UpToDate topics are updated every four months. The editors select a small number of the most important updates and share them via \"What's new\" page<\/a>. I selected the brief excerpts below from What's new in hematology<\/a>:<\/p>

Transplantation in aplastic anemia<\/b><\/p>

In patients with severe aplastic anemia over the age of 40 who received allogeneic hematopoietic cell transplantation from an HLA-identical sibling, overall survival was 65 percent.<\/p>

Improved survival when rituximab is added to fludarabine plus cyclophosphamide in CLL<\/b><\/p>

There were higher response rates and survival with six courses of FCR (fludarabine, cyclophosphamide, and rituximab) when compared with six courses of FC (fludarabine, cyclophosphamide).<\/p>

Second generation tyrosine kinase inhibitors (TKIs) for CML<\/b><\/p>

Trials comparing dasatinib or nilotinib to imatinib for chronic myeloid leukemia (CML) demonstrated faster and deeper responses with these second generation tyrosine kinase inhibitors.<\/p>

Improved understanding of pathobiology of multiple myeloma<\/b><\/p>

Virtually all multiple myeloma (MM) cases are preceded by a premalignant plasma cell proliferative disorder known as monoclonal gammopathy of undetermined significance (MGUS). The pathobiology of myeloma as a two-step process - first there is the establishment of a limited stage of clonal proliferation (MGUS); then there is progression of MGUS to MM.<\/p>

Denileukin diftitox superior to placebo for relapsed mycosis fungoides<\/b><\/p>

There were better response rates with the recombinant interleukin-2-diphtheria toxin fusion protein denileukin diftitox used for therapy of mycosis fungoides and Sezary syndrome.<\/p>

Survival in sickle cell disease<\/b><\/p>

The estimated survival at 18 years is now 94 percent for those with HbSS or HbS\/beta(0) thalassemia and 98 percent for those with HbSC or HbS\/beta(+) thalassemia.<\/p>

References:
What's new in hematology<\/a>. UpToDate.<\/p>

Posted at Clinical Cases and Images<\/a>. Stay updated and subscribe<\/a>, follow us on Twitter<\/a> and connect on Facebook<\/a>.\"\"<\/p><\/div>

<\/a>
<\/a><\/p>

<\/p>","protected":false},"excerpt":{"rendered":"

35% of UpToDate topics are updated every four months. The editors select a small number of the most important updates and share them via \"What's new\" page. I selected the brief excerpts below from What's new in hematology:Transplantation in aplastic … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246864],"tags":[],"class_list":["post-1052969","post","type-post","status-publish","format-standard","hentry","category-neurology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1052969"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1052969"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1052969\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1052969"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1052969"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1052969"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}